Heading to BIO-Europe in Vienna? On Nov 4, don’t miss our session “Accessing the U.S. Market: What’s Ahead for European Biotechs?”. Murray Aitken, head of the IQVIA Institute, will share insights on redefining clinical and commercial strategies amid regulatory shifts, the Inflation Reduction Act, and evolving FDA initiatives, followed by a panel discussion with industry leaders. https://bit.ly/47d9fVh
IQVIA
Hospitals and Health Care
Durham, North Carolina 2,422,682 followers
Accelerate innovation for a healthier world.
About us
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific progress, in an effort to advance healthcare. To learn more, visit www.iqvia.com.
- Website
-
https://www.iqvia.com/
External link for IQVIA
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Public Company
- Specialties
- Technology, Consulting, and Clinical Development
Locations
-
Primary
Get directions
2400 Ellis Rd
Durham, North Carolina 27703, US
Employees at IQVIA
Updates
-
Accuracy, compliance, and value—don’t settle for less in pharma translation. Discover IQVIA’s essential guide to best practices in language procurement. Download our new white paper today: https://bit.ly/46Rypd2
-
-
Dreaming of a career that spans continents and cultures? Take a peek inside IQVIA's Amsterdam office with Ana Batiri as your guide! Ready to join us? Find your role here: https://bit.ly/3JbUOJ0
-
Turning lessons into action: Eight success factors are shaping microbiome therapeutics, sustainable investment, robust evidence, value-based pricing, patient-centric design, stakeholder education, regulatory clarity, scalable manufacturing and collaboration. Read the latest insights today https://bit.ly/46UH8LG
-
-
Agentic AI is opening new possibilities for life sciences. From accelerating clinical trials to improving patient engagement, this technology is reshaping how therapies reach those who need them. Find out how IQVIA AI gets you results faster and powers better patient care in NVIDIA's recent podcast.
🚀 Agentic AI is changing the face of pharma This week’s NVIDIA AI Podcast, IQVIA’s Raja Shankar and Avinob Roy reveal how intelligent automation accelerates trials, improves commercial strategy, and ultimately delivers better patient care. 🎧 Tune in https://nvda.ws/4qujAoL
-
-
A multi-national study revealed over half of older adults in several European countries are prescribed five or more medications - spotlighting the urgent need for better data-driven prescribing strategies. Read the article by IQVIA”s Sophie Jouaville Abrouk to learn more. https://bit.ly/4nqtjtv
-
-
In support of breast cancer awareness month, we’re excited to share a new study in MDM Policy & Practice that includes IQVIA co-authors Laurie Batchelder, Eirini Anastasaki, MBA and Corinna Oswald that shows patients with HER2+ early breast cancer prioritize pathological complete response (pCR) in addition to the traditional metric of overall survival (OS) over the ability to undergo breast conserving surgery and the impact of side effects on quality of life. Learn more here: https://bit.ly/4o22dK7
-
Discover the new approach of Index Date Emulation (IDE) when comparing an intervention against untreated patients in External Comparator studies. In this article, IQVIA’s Luis Antunes, Gerd Rippin, Eleanor Ralphs, Artis Luguzis, Kellyn Arnold and Hopin Lee outline how IDE avoids the common problem of immortal time bias and why it may be an advantageous analysis option for many EC studies when comparing against untreated patients." https://bit.ly/4hb7CMh
-
Heading to ObesityWeek® 2025? Don’t miss the chance to meet our dedicated experts across IQVIA, IQVIA Laboratories, and Avacare Clinical Research Network to learn how we can help accelerate your obesity trial timelines. Schedule a meeting with us here: https://lnkd.in/dxTTXgjn
-
Looking for an insider edge in the job market? Join our IQVIA Global Talent Network for exclusive access to custom job alerts, newsletters, our About IQVIA brochure and more. https://bit.ly/42GTAMx. #WeAreIQVIA